Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Less acidic dye may reduce pancreatitis risk after common procedure

NCT ID NCT07391787

Disease control Sponsor: Shandong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether using low-acid contrast media (dye) during ERCP can lower the chance of developing pancreatitis afterward. Researchers reviewed records of nearly 4,000 patients from five hospitals. They compared patients who received low-acid contrast media to those who received standard contrast media. The goal is to find a safer option for this common procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ioversol, Iohexol (low-acid contrast media)
What this could lead to
If low-acid contrast media works, it could offer a simple way to lower the risk of pancreatitis after ERCP, making the procedure safer.
What could go wrong
This is a retrospective study, not a controlled trial, so results may be influenced by other factors. The benefit may be small or not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3,979 people

The number who actually took part.

Started

Aug 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A total of approximately 3,881 eligible ERCP patients were included from five tertiary Grade A centers. All patients signed the informed consent form. Specifically, 2,305 patients were from Qilu Hospital of Shandong University, 463 from Linyi People's Hospital, 121 from Qilu Third Hospital of Shandong University, 106 from Dezhou Hospital of Qilu Hospital of Shandong University, and 886 from Shengli Oilfield Central Hospital.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 to 90 years who underwent ERCP diagnostic and therapeutic procedures were included consecutively. Exclusion Criteria: * Patients who did not use contrast media during ERCP * Failed ERCP papillary intubation * Patients with acute pancreatitis within 3 days before ERCP * ERCP stent removal/replacement * Patients who had a history of pancreaticoduodenectomy or biliary-enteric anastomosis * Patients whose postoperative amylase/lipase levels could not be traced.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-ercp acute pancreatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute pancreatitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-ercp acute pancreatitis

Contacts and locations

Locations

  • Department of Gastroenterology, Qilu Hospital, Shandong University

    Jinan, Shandong, 250012, China

  • Qilu hospital, Shandong University

    Jinan, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.